REimagining a World of Possibilities

At BUZUD, we see the world not just as it is, but as it could be. We are driven by a relentless desire to REimagine possibilities—challenging boundaries and envisioning solutions that truly make a difference. Innovation is at the heart of what we do, as we continuously REinvent the way we empower individuals and uplift communities, creating meaningful change that lasts.

But transformation doesn’t stop there. At BUZUD, we believe in the power to REnew—to breathe fresh energy into every step we take, to inspire hope, and to create opportunities for a brighter tomorrow. We are not just shaping the future; we are rethinking it, one bold idea at a time. Through innovation, compassion, and purpose, we are building a world where every action leads to lasting impact.

Our Chinese name, 邦助, beautifully reflects our purpose and values. "邦" symbolises unity, connection, and the strength that comes from working together, while "助" signifies support, care, and the unwavering commitment to uplifting those around us. Together, these characters embody our role as a trusted partner, standing shoulder to shoulder with the individuals and communities we serve. They represent our dedication to fostering collaboration, empowering progress, and creating a future where compassion and innovation go hand in hand.

In line with our goal to REnew lives, we have also extended our support to individuals and families managing their health and well-being within the comfort of their own homes. Our sub-brand, 伴助, is dedicated to providing high-quality homecare solutions, offering both companionship and care for easy, holistic support.

At BUZUD, we are more than just a name—we are a promise to inspire, support, and drive meaningful change that resonates far beyond today.

Committed to advance health and empower people worldwide to live life to the fullest, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment. Aiming to realize its vision “Going for Zero, Preventive Care for the Health of Society”, the company develops products and services for cardiovascular condition management, remote patient monitoring , respiratory care, and pain therapy devices. These help healthcare professionals and patients to reduce cerebrocardiovascular events, aggravation of respiratory diseases and restrictions due to chronic pain.

With well over 350 million units sold globally*, OMRON provides the world’s most recommended blood pressure monitors by healthcare professionals**. Throughout its history, OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions and provides products and services in over 130 countries***.

OMRON Healthcare Group is headquartered in Kyoto, Japan.

For more information on OMRON’s Healthcare business in Singapore, please visit OMRON’s website at https://www.omronhealthcare-ap.com/sg

* Cumulative sales of home-use digital blood pressure monitors worldwide. (as of May 2023)
** 1 Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys. (November 25, 2019, and U.S. News Staff 2020, U.S. News & World Report, accessed June 9, 2020)
** 2 Kantar Health. Survey with cardiologists. (2019)
*** Number of the countries where OMRON products and/or services are available (as of March 2023)

At HELF, we’re building cutting-edge medical AI to tackle some of the world’s most urgent healthcare challenges. Our mission is to make medical knowledge more accessible, accurate, and fair so that more people everywhere can get the care they deserve. We believe AI should empower, not replace, human healthcare. That is why we design systems that support clinicians, improve decision-making, and serve patients equitably across all communities.

Rebee Health: Transforming Remote Physiotherapy

Rebee Health provides advanced remote monitoring solutions for patients undergoing physical rehabilitation after injury or surgery. Our innovative system combines wearable sensors with an intuitive mobile app to deliver remote physiotherapy with real-time feedback, ensuring exercises are performed correctly and consistently.

For healthcare professionals, Rebee offers a digital platform to track patient progress and adjust rehabilitation programs remotely using key data insights such as range of motion, compliance, pain levels, and patient outcomes. This data-driven approach enhances patient care while optimizing clinical efficiency.

Key Areas Where Rebee Delivers Impact:
• Chronic pain management
• Neurological, orthopedic, oncology, geriatric, and cardiovascular rehabilitation
• Muscle deconditioning and recovery from long-term hospitalization

By improving compliance with home rehabilitation programs, Rebee enhances mobility, reduces chronic pain, and increases patient engagement. It also expands access to physiotherapy, reduces hospital wait times, and improves recovery outcomes—all while increasing therapist productivity.

Rebee is shaping the future of rehabilitation—empowering patients, supporting healthcare professionals, and transforming the delivery of remote physiotherapy.

For more information, visit rebeehealth.com.

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology aims to allow for continuous monitoring and disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

Digital Life Line: Smarter, Scalable Vision Screening for Every Level of Care

Digital Life Line is a healthtech startup dedicated to eliminating avoidable blindness through compact, AI-powered tools that bring clinical-grade vision screening to both primary and tertiary care settings. Our mission is to enable early, accurate detection of vision problems—anytime, anywhere.

Our flagship innovation is AVAT—the Automated Visual Acuity Test—a portable, tabletop device that reduces traditional 6-meter vision testing to just 0.5 meters using a patent-pending afocal optics system. AVAT uses adaptive testing algorithms to deliver faster, more precise acuity assessments. It is self-administered, requires no specialist supervision, and is ideal for frontline screening in schools and clinics, as well as routine assessments in hospitals and specialty centers.

We also offer MIDAS—the Mobile Imaging Device for Anterior Segment—a patent-pending, smartphone-attachable tool that enables non-specialists to capture high-quality images of the anterior eye. MIDAS uses LED illumination and intuitive alignment features for consistent video capture. These videos are uploaded to our cloud-based AI portal, which delivers on-the-spot cataract detection in under 20 seconds—empowering frontline health workers to make immediate, informed decisions.

Together, AVAT and MIDAS provide an end-to-end, scalable solution that supports early detection, triage, and referral across diverse care environments. Designed to integrate seamlessly into clinical workflows, our tools align with the Quadruple Aim: improving patient experience, enhancing population health, reducing care costs through early intervention, and supporting providers with efficient, easy-to-use technology.

At APPCRC 2025, we invite you to experience these innovations firsthand at the World Café. With AVAT and MIDAS, Digital Life Line is building the future of accessible vision screening.

SG Diagnostics Pte Ltd is a Singapore-based medical diagnostics company founded in 2020, specializing in point-of-care testing solutions for chronic and infectious diseases. With a mission to improve lives through quality diagnostics, SG Diagnostics aims to make accurate testing accessible to anyone, anytime, anywhere.
The company’s product portfolio includes devices for diabetes management, such as HbA1c analysis systems, cholesterol monitoring systems, and rapid test kits for infectious diseases like COVID-19 and influenza. SG Diagnostics also offers multi-drug rapid urine test panels for drug abuse detection. These products are designed to empower healthcare providers with timely and accurate diagnostic tools, enhancing patient care across various settings.

SG Diagnostics solutions are widely used in Singapore by leading healthcare providers, including Raffles Medical, demonstrating the company’s ability to meet the rigorous demands of the healthcare industry. Building on this success, SG Diagnostics is actively expanding its operations into other key markets, such as Hong Kong and Australia, to extend the reach of its quality diagnostic solutions.

By focusing on accessible and accurate diagnostic technologies, SG Diagnostics bridges gaps in care delivery and improves the quality of life for patients. Through strong partnerships with healthcare providers and an unwavering commitment to innovation, the company continues to deliver diagnostic solutions that meet the evolving needs of modern healthcare systems.

Nisshinbo Singapore, a subsidiary of Nisshinbo Holdings Inc., drives innovation in healthcare and infrastructure by leveraging advanced technologies. The company focuses on enhancing product performance, miniaturisation, and energy efficiency, aligning with global trends in smart devices and connectivity. In healthcare, Nisshinbo Singapore develops cutting-edge patient vital signs monitoring systems that deliver real-time data, improving diagnosis and treatment accuracy. Its R&D efforts prioritise user-friendly and accessible solutions. By combining technological expertise with a commitment to sustainability, Nisshinbo Singapore plays a pivotal role in shaping thefuture of healthcare, delivering impactful solutions for a smarter, more connected world.

Mesh Bio is a healthtech startup specializing in predictive analytics and digital twin technology to advance precision medicine and preventive healthcare. Our flagship solution, HealthVector Diabetes (HVD), is a digital twin Software as a Medical Device (SaMD), which predicts the risk of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM), enabling early intervention and personalized care. Our advanced clinical analytics and automation solutions empower providers to deliver more effective personalized and preventive care, improving patient outcomes and reducing healthcare costs.

Empowering Better Health Care with Digital Innovation

Slice of Life Ventures, was founded to seamlessly integrate advanced digital health technology into everyday medical care, leading to tangible improvements for both practitioners and patients. We are driven by a core belief that technology should empower, simplify, and elevate care, aligning company growth with creating positive societal impact. Our commitment is to deliver: Better Health Outcomes: Enabling more proactive, personalized care Improved Access to Care: Streamlining patient pathways and extending the reach of quality health support. Enhanced Well-being: For both patients and the doctors managing their complex needs. Operational Efficiency & Cost Savings: Optimizing workflows and reducing unnecessary expenditures. Greater Convenience: For patients managing their health and for practices managing their caseloads.

Our offerings are structured through two key avenues: Our B2C direct-to-consumer platform, Healthzip, empowers patients to take a more active role in their health journey. Healthzip is a tool that assists individuals with organizing personal health data, serves as invaluable aids for caregivers, supports personal fitness goals, and provides robust assistance in managing chronic conditions. By engaging patients directly, we can provide doctors with medical history, so they can make faster and more accurate diagnosis for their patients, enhance diagnostic accuracy, improve patient safety, save time during the appointment and minimize their mental and administrative burden. Our B2B solution, Foodie, is rooted in evidence based research to provide hospitals and institutions with sophisticated AI-powered patient nutrition management tools and data analytics platforms.

Slice of Life Ventures is committed to being a trusted partner for doctors and health care providers, with digital health solutions that advance medical capabilities and support the vital work of delivering high-quality, patient-centered care. We believe in creating technology that assists, amplifies the doctor's expertise, helps in managing complexity, improves outcomes, and builds stronger, healthier communities.

When our health is at risk, we rely on physicians to make the best possible decisions – from quick, early diagnoses to the most effective treatments and follow-ups. By constantly bringing breakthrough innovations to market, we help healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.

Our portfolio of products, services, and solutions is at the center of clinical decision-making and treatment pathways. Patient-centered innovation has been and always will be at the core of our company. We aspire to create better outcomes and experiences for patients no matter where they live or what they are facing.

This is why we give our best every day, to improve the lives of patients and their families.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.

TIIM Healthcare is a Singapore-based health technology company focused on transforming emergency care through clinically validated, AI-powered decision support tools. Our flagship product, aiTriage, is a regulatory-grade Software as a Medical Device (SaMD) designed to support fast, accurate triage of chest pain patients in Emergency Departments (EDs) and urgent care settings.

Chest pain is the second most common reason for ED visits worldwide, yet more than 90% of patients are low-risk and often undergo prolonged testing and observation. aiTriage addresses this by delivering a real-time 30-day Major Adverse Cardiac Event (MACE) risk prediction using only a 5-minute ECG and vital signs. A troponin test may be optionally included to enhance accuracy but is not required — enabling faster triage even before lab results are available.

Unlike conventional scores like HEART or TIMI, which rely on manual scoring and require a series of blood tests, aiTriage provides fully automated predictions at the point of care. Its ability to forecast near-term cardiac events supports early discharge of low-risk patients and timely escalation for high-risk cases — improving outcomes, reducing ED congestion, and optimizing clinical resources.

Clinically validated and workflow-ready, TIIM Healthcare’s solutions are actively expanding across Southeast Asia, North America, and MENA. We welcome partnerships with healthcare providers, research institutions, and strategic investors committed to scalable innovation in acute care.

Biomedica is a health technology company specializing in AI-powered disease screening solutions, with a primary focus on osteoporosis detection in the primary care setting. Our mission is to empower healthcare professionals with accurate, efficient, and accessible tools to support early diagnosis, improve patient outcomes, and ease the burden on specialist care.

Our flagship AI solution enables primary care providers to screen for osteoporosis using existing imaging and clinical data—without the need for dedicated DXA scans. This non-invasive, cost-effective approach allows for timely risk stratification and proactive management, making it ideal for integration into routine care workflows. By identifying at-risk patients earlier, clinicians can intervene before fractures occur, significantly improving long-term outcomes for aging populations.

In Singapore, Biomedica supports national healthcare priorities focused on preventive care and chronic disease management. Our solution is particularly relevant in the primary care context, where early screening can have the most impact. Through our partnership with Gradient Health & Technologies Pte Ltd (GHT), we ensure localized support for implementation, technical integration, clinician training, and ongoing service. GHT’s expertise ensures our technology fits seamlessly into the workflows of Singapore’s primary care providers.

Beyond osteoporosis, Biomedica’s AI platform has the potential to support screening for a wide range of diseases, including Sarcopenia, Bone Fracture, and Smart NGS solution for Breast Cancer and Cervical Cancer. Our modular, scalable system is designed for future adaptability, enabling healthcare providers to address multiple disease risks using a single platform—making it a powerful tool for comprehensive preventive care.

Together, Biomedica and GHT are redefining disease screening in primary care by delivering precise, practical, and AI-driven solutions. Our vision is to bring advanced diagnostic support to the frontlines of healthcare, enabling earlier interventions, reducing healthcare costs, and ultimately improving the health and well-being of communities in Singapore and beyond.

Health BETA's genomic digital therapeutics focuses on the prevention of chronic diseases through personalized, data-driven risk assessment. By integrating genetic insights with lifestyle and health information, our solution empowers individuals and healthcare providers to take early, targeted action—before chronic conditions like coronary artery disease (CAD), diabetes, and hypertension develop or worsen.

Our platform offers an accessible, preventive tool designed to support healthier choices and long-term health planning. It enables users to understand their individual risk profiles and track how lifestyle adjustments influence their disease risk over time, creating a continuous feedback loop for prevention-focused care.

Health BETA aims to further advance the science of disease prediction by establishing gene-environment interaction models that reflect how inherited and modifiable factors jointly impact chronic disease onset. This roadmap positions us to contribute meaningfully to the future of precision health—enabling early, accurate, and actionable prevention at scale.